Symptomatic Vitreomacular Adhesion
Also known as: Symptomatic Vitreomacular Adhesion (VMA)
Drug | Drug Name | Drug Description |
---|---|---|
DB08888 | Ocriplasmin | A proteolytic enzyme used to treat symptomatic vitreomacular adhesion by dissolving the protein matrix responsible for the adhesion between the vitreous and macula. |
Drug | Drug Name | Target | Type |
---|---|---|---|
DB08888 | Ocriplasmin | Alpha-2-macroglobulin | target |
DB08888 | Ocriplasmin | Alpha-2-antiplasmin | target |
DB08888 | Ocriplasmin | Fibronectin | target |
Drug | Drug Name | Phase | Status | Count |
---|---|---|---|---|
DB08888 | Ocriplasmin | 3 | Completed | 1 |
DB08888 | Ocriplasmin | Not Available | Completed | 1 |